Ibrutinib,Rituximab,venetoclax
roche,janssen,abbvie,biogen
['cll', 'ibru', 'leusm', 'venetoclax']
ibrutinib plus venetoclax produces high mrd negativity rate in previously untreated cll #eha22 #leusm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.